Anticarcinogenic and antiplatelet effects of carvacrol
Loading...
Date
Authors
Karkabounas, S.
Kostoula, O. K.
Daskalou, T.
Veltsistas, P.
Karamouzis, M.
Zelovitis, I.
Metsios, A.
Lekkas, P.
Evangelou, A. M.
Kotsis, N.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Exp Oncol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
AIM: To investigate the effect of carvacrol on chemical carcinogenesis, cancer cell proliferation and platelet aggregation, and to find possible correlation between all these processes and the antioxidant properties of carvacrol. MATERIALS AND METHODS: 3,4-benzopyrene-induced carcinogenesis model using Wistar rats was used. Leiomyosarcoma cells from Wistar rats were used to study carvacrol antiproliferative activity in vitro. The carvacrol antiplatelet properties were investigated with platelet aggregation assay and flow cytometry technique. The production of thromboxane B2, final metabolite of platelet aggregation, was evaluated by radioimmunoassay. RESULTS: Our study revealed significant anticarcinogenic properties of carvacrol. We observed 30% decrease of 3,4 benzopyrene carcinogenic activity in vivo. Antiproliferative activity of carvacrol (IC(50)) was 90 microM and 67 microM for 24 h and 48 h of incubation of cells, respectively. Carvacrol possessed also mild antiplatelet effect, inducing the decrease of thromboxane A2 production in platelets and as a result - restrictive expression of the GPIIb/IIIa platelet receptor. CONCLUSION: Our data demonstrated that carvacrol possesses anticarcinogenic, antiproliferative and antiplatelet properties.
Description
Keywords
Animals, Anticarcinogenic Agents/pharmacology/*therapeutic use, Benzo(a)pyrene/toxicity, Blood Platelets/drug effects/metabolism, Cell Proliferation, Leiomyosarcoma/chemically induced/*prevention & control, Male, Monoterpenes/pharmacology/*therapeutic use, Platelet Aggregation/*drug effects, Platelet Aggregation Inhibitors/pharmacology/*therapeutic use, Rats, Rats, Wistar, Thromboxane B2/analysis/antagonists & inhibitors
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/16837902
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής